Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMA Suspends Some Activities & Warns That High Job Losses Could Halt Its Operations

Executive Summary

Some regulatory activities have been on hold at the European Medicines Agency as it prepares for the impact of the UK’s departure from the EU. The EMA is also concerned that unexpectedly high staff losses will seriously affect its ability to operate.

You may also be interested in...

Brexit Bites EMA: Huge Staff Losses Freeze Many Projects

The EMA is halting its cherished transparency initiative on study data as it reckons with the fact that many of its employees will not be relocating to its new headquarters in Amsterdam. International collaboration, guidelines development and revision, and the agency's involvement in stakeholder meetings will all be cut back.

EMA To Re-Prioritize Tasks To Cope With ‘Higher Than Expected’ Staff Losses

The EMA is to further refocus on its core activities to help it deal with “higher than expected” staff losses due to its relocation to Amsterdam.

Dutch Delegation Promises ‘Seamless’ Transition To EMA’s New Home

Dutch officials took part in the December meeting of the EMA management board and presented details of their plans for the agency’s relocation to Amsterdam. The board also adopted the 2018 work program and budget, which allow for a 6.8% rise in fee-related revenue next year, and said phase 2 of the Brexit business continuity plan would begin in January.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts